share_log

Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $49

Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $49

摩根士丹利維持kymera therapeutics的等權重評級,將目標股價上調至49美元
Benzinga ·  2024/11/06 20:27  · 評級/大行評級

Morgan Stanley analyst James Quigley maintains Kymera Therapeutics (NASDAQ:KYMR) with a Equal-Weight and raises the price target from $45 to $49.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論